Examination of GyE system for HIMAC carbon therapy

Kanai, Tatsuaki; Matsufuji, Naruhiro; Miyamoto, Tadaaki; Mizoe, Jun‐etsu; Kamada, Tadashi; Tsuji, Hiroshi; Kato, Hirotoshi; Baba, Masayuki; Tsujii, Hirohiko

doi:10.1016/j.ijrobp.2005.09.043

Cited by 147 publications

(130 citation statements)

References 19 publications

Supporting

Mentioning

129

Contrasting

Order By: Relevance

“…The carbon‐ion beam and the proton beam have a high dose concentration, and CIRT can deliver significantly higher target conformity while sparing normal liver tissue in comparison with SBRT 14. In addition, the carbon‐ion beam has a higher biological effect because of inherently high linear energy transfer radiation; this distinguishes it from proton and X‐ray beams 15, 16. However, to date, there remains a lack of evidence for the safety and efficacy of CIRT for patients with HCC.…”

Section: Introductionmentioning

confidence: 99%

Progressive hypofractionated carbon‐ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials

Kasuya

Kato²,

Yasuda

et al. 2017

Cancer

Self Cite

View full text Add to dashboard Cite

BACKGROUNDThe objective of this study was to evaluate the safety and efficacy of carbon‐ion radiotherapy (CIRT) in patients with hepatocellular carcinoma (HCC) with stepwise dose escalation and hypofractionation in 2 combined prospective trials.METHODSSequential phase 1/2 (protocol 9603) and phase 2 (protocol 0004) trials were conducted for patients with histologically proven HCC. The phase 1 component of protocol 9603 was a dose‐escalation study; CIRT was delivered in 12, 8, or 4 fractions. After determination of the recommended dose, 2 phase 2 trials were performed in an expanded cohort, and the data were pooled to analyze toxicity, local control, and overall survival.RESULTSIn the phase 1 component of protocol 9603, 69.6, 58.0, and 52.8 Gy (relative biological effectiveness [RBE]) in 12, 8, and 4 fractions, respectively, constituted the maximum tolerated doses, and 52.8 Gy (RBE) in 4 fractions was established as the recommended dose regimen for the 2 phase 2 studies. In 124 patients with a total of 133 lesions, few severe adverse effects occurred, and local‐control and overall survival rates at 1, 3, and 5 years were 94.7% and 90.3%, 91.4% and 50.0%, and 90.0% and 25.0%, respectively; this included 1‐, 3‐, and 5‐year local‐control rates of 97.8%, 95.5%, and 91.6%, respectively, in the phase 2 study. In a multivariate analysis, Child‐Pugh class B and the presence of a tumor thrombus were significant factors for mortality.CONCLUSIONSThe safety and efficacy of CIRT in 12, 8, and 4 fractions were confirmed, with 52.8 Gy (RBE) in 4 fractions established as the recommended treatment course for eligible HCC patients. Cancer 2017;123:3955‐65. © 2017 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.

show abstract

Section: Introductionmentioning

confidence: 99%

Progressive hypofractionated carbon‐ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials

Kasuya

Kato²,

Yasuda

et al. 2017

Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…The margin was set by inferior respiratory displacement results obtained before respiratory movement. The radiation dose was in the range of 66-76 Gy equivalent (GyE) (mean dose 70 GyE) [21]. The ion beams were a proton beam of 150 or 210 MeV and a carbon beam of 320 MeV.…”

Section: Ion Beam Therapymentioning

confidence: 99%

Preliminary study of apparent diffusion coefficient assessment after ion beam therapy for hepatocellular carcinoma

Kanamoto

Miyati

Terashima

et al. 2016

Radiol Phys Technol

View full text Add to dashboard Cite

We evaluated the state of hepatocellular carcinoma (HCC) and the liver after ion beam therapy by analyzing the apparent diffusion coefficient (ADC). In this retrospective study, we evaluated 13 HCC lesions in 10 patients who underwent magnetic resonance imaging before and after therapy. Diffusion-weighted imaging was performed with use of b values of 0, 150, and 800 s/mm 2 . The ADC was determined for the tumor, irradiated liver, and normal liver. The maximum size of the tumor was measured, and reduction in tumor size was determined as a ratio of the maximum size of the diameter of the tumor. We compared the ADC before and after the therapy with the reduction in tumor size ratio. The reduction in tumor size ratio was compared with the ADCs of the tumors. The ADC of the tumor and the irradiated liver were significantly higher after therapy than before therapy. The ADC of the normal liver was not significantly different before and after therapy. The reduction ratio increased significantly (R = 0.73, P = 0.006) after therapy at the second follow-up when compared with after therapy at the first follow-up. No correlation was found between the reduction ratio and the ADC of the tumor in each follow-up. Inflammation of the liver occurs after treatment as a result of radiation doses from the ion beam, and the tumor reaches a state of necrosis. ADC value analysis provides a non-invasive assessment and yields focal information regarding the tumor and liver before and after ion beam therapy.

show abstract

“…The RBE of neutron and carbon ions is difficult to calculate and for dose-reporting purposes a value of 3 is often utilized. 24 There is extensive literature on the use of particles in the treatment of prostate cancer. There appears to be two distinct clinical advantages that particle beams could offer over traditional photon therapy.…”

Section: Physical and Radiobiological Characteristics Of Particlesmentioning

confidence: 99%

“…Dose expressed in GyE is the product of the carbon ion physical dose and the RBE value of 3.0. 24 A total of 96 patients were accrued in this study. No patients presented grade 3 acute morbidity.…”

Section: Particle Therapy In Prostate Cancer C Grecomentioning

confidence: 99%

“…20 Indeed, carbon-ion data compare favorably with published results for equivalent doses with Xrays, and in fact, the RBE for carbon ions may exceed 3.0. 24 The effect of alterations in dose fractionation schedule for charged particles is difficult to estimate. With the arbitrary assumption that the linear quadratic model may be applied to carbon ions similarly to photons, the BED of total dose of 66 GyE in 20 fractions would be equivalent to a normalized total dose of 90.5 Gy at 2 Gy fractions with a a/b of 1.5.…”

Section: Particle Therapy In Prostate Cancer C Grecomentioning

confidence: 99%

See 1 more Smart Citation

Particle therapy in prostate cancer: a review

Greco

2007

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

While dose escalation is proving important to achieve satisfactory long-term outcomes in prostate cancer, the optimal radiation modality to deliver the treatment is still a topic of debate. Charged particle beams can offer improved dose distributions to the target volume as compared to conventional 3D-conformal radiotherapy, with better sparing of surrounding healthy tissues. Exquisite dose distributions, with the fulfillment of dose-volume constraints to normal tissues, however, can also be achieved with photon-based intensity-modulated techniques. This review summarizes the literature on the use of particle therapy in prostate cancer and attempts to put in perspective its relative merits compared to current photon-based radiotherapy.

show abstract

Examination of GyE system for HIMAC carbon therapy

Cited by 147 publications

References 19 publications

Progressive hypofractionated carbon‐ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials

Progressive hypofractionated carbon‐ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials

Preliminary study of apparent diffusion coefficient assessment after ion beam therapy for hepatocellular carcinoma

Particle therapy in prostate cancer: a review

Contact Info

Product

Resources

About